How Effective Are PRP Injections for Tennis Elbow?

Platelet-rich plasma injections for tennis elbow occupy an awkward middle ground in the evidence: they consistently outperform cortisone shots over the long term, but when tested against a simple saline placebo, the advantage shrinks or disappears. That tension sits at the heart of the PRP debate for lateral epicondylitis, and understanding it matters if you’re weighing your treatment options. The picture becomes more interesting when you look at imaging studies, cost analyses, and comparisons with other treatments like shockwave therapy and surgery.

What PRP Is Meant to Do Inside Your Tendon

Tennis elbow is not really an inflammation problem, despite its older name “lateral epicondylitis” (the “-itis” suffix implies inflammation). It’s a degenerative tendon condition, a breakdown in the common extensor tendon where it attaches to the bony bump on the outside of your elbow. The tissue shows failed healing rather than active swelling, which is why treatments that just suppress inflammation tend to fall short over time.¹

PRP is a concentrate of your own platelets, drawn from a blood sample and spun in a centrifuge to separate and concentrate them. When platelets are activated, they release growth factors from tiny storage packets called alpha granules. The theory is straightforward: deliver a burst of those growth factors directly into the damaged tendon, and you might restart or accelerate the body’s stalled repair process.² It’s an appealing idea, and it has some real biological logic behind it. Whether that logic translates into clinical results is where things get complicated.

PRP Versus Cortisone Shots

This is the comparison most people care about, since cortisone injections have been the go-to treatment for decades. The pattern across multiple studies is remarkably consistent: cortisone wins early, PRP wins late.

A meta-analysis pooling results from several trials found that cortisone injections produced better pain and function scores at four and eight weeks. But at roughly six months, the picture flipped, and PRP injections showed significantly better outcomes.³ A systematic review looking at the same question found the same crossover: cortisone’s maximum effect appeared around six to eight weeks before symptoms came back, while PRP showed slower but ongoing improvements stretching out to one and even two years.⁴

A prospective triple-blinded trial confirmed this timeline more precisely: the steroid group scored better at three months, but the PRP group scored better at two years.⁵ And in a well-known double-blind trial with two-year follow-up, the PRP group was significantly more often classified as “successfully treated” than the cortisone group, with success defined as at least a 25 percent reduction in pain or disability scores without needing another procedure.

This trade-off has real practical implications. If you need quick relief for an important event or work deadline, cortisone delivers faster. But cortisone’s benefits tend to fade, and there’s growing evidence that repeated cortisone injections can actually weaken tendons. PRP’s slower payoff may reflect something closer to genuine tissue repair rather than symptom suppression. That said, the PRP-versus-cortisone story has a wrinkle that’s easy to miss.

The Placebo Problem

Here’s the part that complicates the narrative: PRP consistently beats cortisone over the long haul, but it does not consistently beat a placebo injection. A meta-analysis of randomized placebo-controlled trials found no significant difference between PRP and placebo injections for either pain relief or functional improvement in chronic lateral epicondylitis.⁶

A rigorous randomized trial compared PRP, cortisone, and saline injections and found that all three groups improved, with no statistically significant differences between them at three months.⁷ In other words, sticking a needle into the sore tendon and injecting salt water worked about as well as injecting concentrated platelets.

How do you reconcile “PRP beats cortisone” with “PRP doesn’t beat saline”? A few explanations are plausible. Tennis elbow has a high natural resolution rate over time, so many people in all groups improve regardless of what’s injected. Cortisone may look good early but actually impair long-term healing, meaning PRP’s advantage over cortisone at two years might partly reflect cortisone making things worse rather than PRP making things better. And the needle itself, puncturing the tendon, can trigger a local bleeding and healing response that acts as a form of treatment on its own. The Cochrane review on this topic was blunt: with low-certainty evidence showing no clear benefit over placebo and similar adverse event rates, the costs and risks of PRP injection “are not justified.”⁸

That Cochrane assessment represents the most conservative reading of the evidence. Not everyone agrees with it, and some of the newer trial data tells a more nuanced story.

How PRP Stacks Up Against Physiotherapy, Shockwave, and Prolotherapy

A prospective randomized trial with two-year follow-up compared PRP to three other treatments: physiotherapy, extracorporeal shockwave therapy, and prolotherapy (sugar-water injections meant to provoke a healing response). At 24 months, all four treatments produced clinically meaningful improvements in disability scores, but PRP produced the largest gains by a considerable margin. PRP reduced disability scores by about 31 points, compared with roughly 19 for physiotherapy and 18 for shockwave. Prolotherapy also outperformed physiotherapy and shockwave at 24 months, though not by as much as PRP. Patients in the PRP group also reported the highest subjective satisfaction scores.⁹

This study is worth noting because it included active comparators rather than just saline, and PRP still came out ahead. The prolotherapy result is interesting too: a simple sugar-water injection, which mainly irritates the tissue into mounting a repair response, also performed well. That raises the same question from a different angle about how much of PRP’s benefit comes specifically from the platelets versus the needle and the injection stimulus.

PRP Versus Autologous Blood

Before PRP became widely available, some practitioners injected whole blood drawn from the patient’s arm directly into the tendon, on the theory that any blood products would deliver some growth factors. A network meta-analysis found no significant difference between PRP and whole-blood injections across most outcome measures, though whole blood actually had slightly better results on one disability score. Whole-blood injection did carry a higher rate of adverse effects.¹⁰ A head-to-head trial comparing the two found PRP gave modestly better pain improvement at six weeks, but no significant difference on overall elbow function scores.¹¹

The similarity between PRP and whole blood is one reason some researchers suspect the needle fenestration itself, the repeated puncturing of the degenerative tendon, is a meaningful part of the therapeutic effect. When you can get a similar result from plain blood as from a concentrated platelet product, the “concentrated growth factors” story becomes harder to maintain as the sole explanation.

What Imaging Shows After PRP Injection

One of the more compelling pieces of the PRP story comes from imaging studies that tracked tendon changes over time. A study using repeated MRI at six time points over two years found continuous, progressive tendon recovery. Mean MRI scores improved significantly by three months and kept improving at every follow-up through 24 months, at which point the tendons looked close to normal on imaging.¹²

Ultrasound-based studies have shown similar structural improvements. One study using ultrasound-guided PRP injections found significant improvements in tendon echotexture, thickness, and partial tears in the majority of patients.¹³ A case series using ultrasound-guided injection reported pain relief by four weeks, with continuing functional improvement over three months, and ultrasonography confirmed that the damaged tendons had been repaired.¹⁴

Newer research is exploring quantitative imaging biomarkers, using advanced ultrasound texture analysis and MRI T2 profiling, that can detect tendon remodeling with more precision than a clinician simply eyeballing a scan. Early results suggest these tools capture PRP-induced changes that standard imaging misses, which could eventually help clinicians decide who’s a good candidate and track whether treatment is working.¹⁵

The imaging data is genuinely encouraging, but it comes with a caveat: these studies generally lack placebo-controlled comparisons. We know tendons look better on MRI after PRP, but we don’t have robust imaging data showing they look better than they would after saline or no injection at all over the same timeframe. Tennis elbow does heal on its own for many people, so some of the structural improvement could reflect natural recovery.

PRP Versus Surgery

For people whose tennis elbow hasn’t responded to conservative treatment, surgery is usually the last resort. A systematic review looking at PRP versus surgical intervention found that two studies reported similar pain and functional outcomes between PRP injections and surgery in the short and mid-term, and one study found similar results in terms of return to work. However, one study suggested surgery may be the better long-term solution.¹⁶ For someone facing the prospect of an operation, getting comparable short-term results from an injection with minimal downtime is appealing, though the evidence base here is still thin.

Does the Type of PRP Matter?

Not all PRP preparations are the same. The two main varieties differ in whether they include white blood cells (leukocytes) along with the platelets. Leukocyte-rich PRP contains a significant concentration of white blood cells, while leukocyte-poor PRP filters most of them out. There’s been active debate about which works better for tendons, since white blood cells release inflammatory molecules that could either help or hinder healing depending on the context.

A systematic review found that both types produced significant improvements in pain and function for lateral epicondylitis, with no significant difference between them. The main practical distinction was that leukocyte-poor PRP caused fewer post-injection pain flares.¹⁷ A network meta-analysis initially found an advantage for leukocyte-rich PRP, but that advantage disappeared when trials at high risk of bias were excluded, suggesting the finding was preliminary and not something to base treatment decisions on.¹⁸

In practice, which formulation you receive often depends on which centrifuge system your doctor’s office uses. Different commercial kits produce different platelet concentrations and leukocyte profiles. This variability across clinics is one reason the research has been hard to compare across trials and one reason two people can have very different experiences with “the same” treatment.

What You Should Know Before Getting a PRP Injection

If you and your doctor decide to try PRP, there are a few practical things worth knowing about medication timing. Platelets release their healing cargo through a process called degranulation, and certain painkillers interfere with that process. A systematic review found that nonselective NSAIDs (the common over-the-counter type, like ibuprofen and naproxen) significantly reduced platelet aggregation, while COX-2 selective NSAIDs did not. Acetaminophen (Tylenol), statins, and aspirin did not significantly reduce platelet counts.¹⁹

A detailed review of individual NSAIDs found that the length of time you need to stop them varies by drug. Naproxen suppressed platelet function for at least 24 hours and possibly up to 48, while ibuprofen and diclofenac inhibited aggregation for 6 to 12 hours depending on dose. Indomethacin showed recovery by 24 hours. Acetaminophen, which only mildly affects the relevant enzyme, doesn’t require deferral at all.²⁰ If you’re using ibuprofen regularly for your elbow pain, your doctor will likely ask you to stop it at least a day or two before the procedure. The irony isn’t lost on patients: the drug you’ve been taking for the pain could undermine the treatment meant to fix it.

The injection itself is usually done with ultrasound guidance, which allows the doctor to see the damaged tendon in real-time and place the PRP precisely at the site of degeneration. Expect some discomfort during the injection and a temporary flare-up of pain for the first few days afterward. Most protocols ask you to avoid anti-inflammatory medications during the recovery period as well, since the controlled inflammatory response is considered part of how the treatment works. A typical timeline involves noticeable improvement starting around four to six weeks, with continued gains over several months.

The Cost Question

PRP injections typically run several hundred dollars out of pocket and are often not covered by insurance, which makes the cost comparison with cortisone (usually covered and cheap) feel lopsided. But a cost-effectiveness analysis using modeling found that PRP was actually the more cost-effective option when long-term outcomes were factored in. From both a healthcare and societal perspective, PRP was economically dominant over cortisone, meaning it produced better outcomes at lower total cost when you accounted for the full downstream expenses of follow-up visits, additional procedures, and lost productivity.²¹

That result depends on the modeling assumptions, and your personal calculus will depend on your insurance coverage, how many cortisone injections you’d otherwise need, and how much time off work your tennis elbow is costing you. For someone who has already failed one or two rounds of cortisone and physical therapy, the upfront cost of PRP becomes easier to justify.

The Safety Profile

Because PRP comes from your own blood, the risk of allergic reaction or disease transmission is essentially zero. The Cochrane review found that adverse event rates with PRP were similar to those with placebo injection: about 19 percent of PRP recipients experienced some kind of adverse event versus 17 percent with placebo, a difference that was not statistically significant.²² The most common side effect is temporary pain at the injection site, which tends to last a few days. As with any injection, there is a small risk of infection, but serious complications are rare in the published literature. Among PRP formulations, the leukocyte-poor version appears to produce fewer post-injection flares than the leukocyte-rich version.²³

Who Might Benefit Most

The typical PRP candidate has had tennis elbow for at least three months, has tried rest and physical therapy without lasting improvement, and wants to avoid or delay surgery. The evidence is weakest for people with mild or recent-onset symptoms, where conservative measures usually succeed on their own. It’s strongest, or at least most practical, for people with chronic refractory cases who have already tried cortisone and found that the relief didn’t last.

Age, severity of tendon damage on imaging, duration of symptoms, and activity demands all likely influence outcomes, but the research hasn’t pinpointed reliable predictive factors yet. The lack of standardized PRP preparation protocols across clinics makes this harder to study. Two patients getting “PRP for tennis elbow” at two different clinics may receive products with very different platelet concentrations, leukocyte content, and injection volumes, placed with varying degrees of precision. Until the field standardizes its approach, individual results will remain difficult to predict from the published averages.